DR. PETER KOUIDES M.D.
Prescription History 1780638775
Internal Medicine - Hematology & Oncology in Rochester, NY
Medicare Part D Prescription History
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. PETER KOUIDES M.D., an active Hematology & Oncology specialist practicing in Rochester, NY. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 152 documented patient claims. Among these therapy options, the most frequently utilized medication is Eliquis, which accounts for 52 claims alone. Use the table below to sort by claims, cost, or utilization compared with the state average; select any medication for its full profile.
| Medication | Prescriptions (2024)Rx (2024) | Avg Cost per FillCost / Fill | Vs. Other NY PrescribersVs. NY Avg |
|---|---|---|---|
| EliquisApixaban | 52 | $1,309.46 | ▼ Less than typical |
About Eliquis: Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. Show more ▾ With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood. An antithrombotic agent. In 2024, this provider wrote 52 Medicare prescriptions for Eliquis, about 60% of the volume of the typical New York prescriber of this medication (86.2). Medicare paid an average of $1,309.46 per fill, versus $874.81 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 126 30-Day Fills standardized to 30-day supplies 3,780 Days of Medication total across all patients in 2024 | |||
| Tranexamic Acid | 28 | $40.76▼ below NY avg | ≈ Typical |
About Tranexamic Acid: This medication is used to treat heavy bleeding during your menstrual period. Show more ▾ Tranexamic acid works by slowing the breakdown of blood clots, which helps to prevent prolonged bleeding. It belongs to a class of drugs known as antifibrinolytics. Tranexamic acid is not a hormone. It does not treat other menstrual or pre-menstrual symptoms. It does not stop your period. It is not a form of birth control and does not protect against sexually transmitted diseases. Antifibrinolytic hemostatic used in severe hemorrhage. In 2024, this provider wrote 28 Medicare prescriptions for Tranexamic Acid, about 83% of the volume of the typical New York prescriber of this medication (33.7). Medicare paid an average of $40.76 per fill, versus $48.38 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the NY average for this medication. 28 30-Day Fills standardized to 30-day supplies 140 Days of Medication total across all patients in 2024 | |||
| Hydroxyurea | 21 | $45.25 | ▼ Less than typical |
About Hydroxyurea: This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Show more ▾ Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas). An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. In 2024, this provider wrote 21 Medicare prescriptions for Hydroxyurea, about half the volume of the typical New York prescriber of this medication (35.9). Medicare paid an average of $45.25 per fill, versus $21.65 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 48.8 30-Day Fills standardized to 30-day supplies 1,464 Days of Medication total across all patients in 2024 | |||
| XareltoRivaroxaban | 21 | $1,020.21 | ▼ Less than typical |
About Xarelto: Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. Show more ▾ It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood. A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME. In 2024, this provider wrote 21 Medicare prescriptions for Xarelto, about half the volume of the typical New York prescriber of this medication (43.6). Medicare paid an average of $1,020.21 per fill, versus $942.48 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 41 30-Day Fills standardized to 30-day supplies 1,230 Days of Medication total across all patients in 2024 | |||
| DopteletAvatrombopag Maleate | 16 | $15,084.40 | ≈ Typical |
About Doptelet: This medication is used by people with chronic liver disease and a certain blood disorder (low platelet count) who are scheduled to have a medical or dental procedure. Show more ▾ Having a low platelet count increases the risk of too much bleeding during certain procedures. This medication increases the production of platelets by your body to help prevent too much bleeding from the procedure. Avatrombopag is also used to treat people with a certain blood disorder known as chronic immune thrombocytopenia-ITP. This is a condition where the amount of platelets in the blood is lower than normal. ITP can lead to serious bleeding problems. This medication increases the production of platelets by your body to help prevent too much bleeding from ITP. Enhances megakaryocytopoiesis. In 2024, this provider wrote 16 Medicare prescriptions for Doptelet, about the same volume as the typical New York prescriber of this medication (16.2). Medicare paid an average of $15,084.40 per fill, versus $13,786.69 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 16 30-Day Fills standardized to 30-day supplies 457 Days of Medication total across all patients in 2024 | |||
| BrukinsaZanubrutinib | 14 | $11,356.75▼ below NY avg | ▼ Less than typical |
About Brukinsa: This medication is used to treat certain cancers (mantle cell lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia, chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphoma). Show more ▾ Zanubrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. A Bruton tyrosine kinase (BTK) inhibitor for treatment of Waldenstrom macroglobulinemia. In 2024, this provider wrote 14 Medicare prescriptions for Brukinsa, about a third of the volume of the typical New York prescriber of this medication (35.6). Medicare paid an average of $11,356.75 per fill, versus $13,440.81 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the NY average for this medication. 14 30-Day Fills standardized to 30-day supplies 420 Days of Medication total across all patients in 2024 | |||
About this data. The prescription history for DR. PETER KOUIDES M.D. is compiled from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescriber Public Use File for calendar year 2024, the most recent federal release. Figures cover prescriptions filled for Medicare Part D beneficiaries only; prescriptions under private insurance, Medicaid, or self-pay plans are not included. Because prescribing decisions are generally consistent across coverage types, this record offers a useful view of the overall Hematology & Oncology prescribing approach at this Rochester, NY practice.
Reading the costs. Drug costs are gross amounts paid to pharmacies under Part D, including both plan and beneficiary payments. They are not the price a patient pays at the pharmacy counter. Medications with fewer than 11 claims are excluded from the federal source data, and state comparisons use the average among NY prescribers of the same medication and form, shown only when at least five prescribers contribute. Always confirm current medications and costs directly with the provider and your plan.
About the medication summaries. Drug use descriptions come from the CMS Medicare Part D Drug Spending Dashboard (2024), and substance definitions from Medical Subject Headings (MeSH) 2026, U.S. National Library of Medicine. They are summaries that do not contain all possible information about a medication and are not individual medical advice. Ask a health care professional about any medication and your specific health needs.
